Pricing Log in Create free account
Saturday 17 October 2026 Export SLN’s income statement to Excel — free account

Silence Therapeutics PLC Sponsored ADR

SLN Healthcare Biotechnology

Silence Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $559,000.00, down 98.7% from fiscal 2024. In the quarter to June 2026, revenue grew 197.2%, EPS grew 54.4% and free cash flow grew 107.0%, each against the same quarter a year earlier.

8.68 0.67 −7.17%
Market cap
$581.1M
P/E
0.0×
Fwd P/E
−7.6×
Dividend yield
—
F-score
2/9
Altman Z
−4.82
Beneish M
45.78
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 581.10
Revenue 0.84
Net Income (59.95)
Free Cash Flow (42.26)
Net Debt (72.05)
Current Ratio 7.42 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (7.62) (negative: loss-making)
P/S ratio 488.70 (above 10: high)
P/B ratio 10.66 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth 25.40% (at or above 15%: strong)
Next Y EPS Growth (17.33%) (below 0%: weak)
Next Y revenue growth (22.48%) (below 0%: weak)
Next 5Y EPS Growth (1.68%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 403×, against a ten-year median of 14.0×; over the ten years it ranged from −0.1× in 2025 to 676× in 2026.
P/S against its own 10 years 92.41%
10-year low 10-year high
P/B against its own 10 years 43.08%
10-year low 10-year high
EV/Sales against its own 10 years 93.48%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 69 147 85 72
Receivables 23 25 22 9
Inventory — — — —
Other 12 15 12 13
103 187 119 94
2023 2024 2025 Q'26
Payables 16 16 13 13
ST’ Debt — — — —
Other 7 0 0 —
22 17 14 13

Compound Annual Growth %

10y 5y 3y
Sales — (39.74%) (70.44%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 39.89% 31.66%

Revenue $m

Mar Jun Sep Dec Year
’26 0 — — — —
’25 0 0 0 0 1
’24 16 1 1 25 43
’23 14 11 4 3 32
’22 8 5 4 5 22
’21 — 11 4 12 17
’20 — 2 — 8 7
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) 2 — — —
’25 (12) (22) (11) (17) (62)
’24 (9) (5) (26) (27) (68)
’23 (9) (19) (6) (15) (49)
’22 (19) (9) (9) (18) (56)
’21 — 19 (8) (14) 9
’20 — 1 — (14) (14)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) 2 — — —
’25 (12) (22) (11) (17) (62)
’24 (9) (5) (26) (28) (68)
’23 (9) (45) (7) (15) (50)
’22 (19) (9) (9) (19) (57)
’21 — 19 (8) (14) 8
’20 — 1 — (14) (14)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.32) (0.26) — — —
’25 (0.60) (0.57) (0.45) (0.25) (1.89)
’24 (0.05) (0.42) (0.75) 0.27 (0.99)
’23 (0.35) (0.36) (0.28) (0.47) (1.45)
’22 (0.35) (0.50) (0.25) (0.46) (1.56)
’21 — (0.32) (0.46) (0.30) (1.83)
’20 — (0.17) — (0.36) (1.53)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 15.00 20.50 7.80 4.55 5.81 1.97

Analyst estimates 2026–2028

Powerpack
High — — — — 22.64 35.00 24.66 18.95 27.72 8.08
People
People Employees — — — 58 74 105 122 109 116 88
Revenue/emp, $m 0.00 0.00 — 0.01 0.10 0.16 0.18 0.29 0.37 0.01
Income, $m
Income, $m Revenue 1 0 — 0 7 17 22 32 43 1
Gross margin, % 59.74 (2,606.80) 0.00 0.00 31.34 39.94 37.83 59.34 72.70 61.54
EBT (13) (7) (35) (38) (46) (63) (59) (53) (44) (89)
EBT margin, % (1,345.71) (23,599.51) 0.00 (9,372.37) (657.81) (369.36) (270.66) (168.35) (102.79) (15,849.91)
Net income (10) 0 (31) 0 (46) (63) (59) (54) (45) (89)
Depreciation 0 1 1 1 1 1 1 1 1 1
Per share, $
Per share, $ Revenue 0.04 0.00 0.00 0.02 0.26 0.58 0.67 0.85 0.94 0.01
Earnings (0.15) (0.12) (1.35) (1.32) (1.53) (1.83) (1.56) (1.45) (0.99) (1.89)
Cash flow (0.52) (0.59) (1.22) 0.11 (0.51) 0.32 (1.75) (1.33) (1.46) (1.32)
Capex 0.00 0.00 0.00 0.00 (0.02) (0.06) (0.02) 0.00 0.00 0.00
Free cash flow (0.52) (0.59) (1.22) 0.11 (0.53) 0.25 (1.76) (1.33) (1.47) (1.32)
Book value 2.82 3.39 2.44 1.46 0.43 0.40 0.85 0.59 2.90 1.32
Shares, m 24 28 23 25 27 30 32 37 46 47
Valuation, ×
Valuation, × P/E 0.00 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.00 0.00 — 0.00 0.00 20.33 21.85 21.74 7.36 513.72
P/B 12.43 12.43 — 12.43 52.52 45.82 17.32 31.29 2.37 4.61
EV/Sales 0.00 0.00 — 0.00 0.00 16.50 17.78 19.57 3.95 361.63
EV/FCF (291.34) (291.34) — (291.34) (108.15) (36.56) (6.83) (12.51) (2.52) (3.24)
Cash, $m
Cash, $m Operating cash flow (12) (17) (29) 3 (14) 9 (56) (49) (68) (62)
Capex (1) 0 0 0 (1) (2) (1) 0 0 0
Free cash flow (12) (17) (29) 3 (14) 8 (57) (50) (68) (62)
Balance, $m
Balance, $m Working capital 50 78 42 48 65 98 92 81 171 105
Total debt — — — 1 1 0 1 0 — —
Net debt (48) (79) (43) (58) (50) (101) (88) (69) (147) (85)
Shareholders’ equity 67 96 57 36 12 12 27 22 134 62
Returns, %
Returns, % ROA (14.55) (8.18) (47.55) (103.54) (48.07) (44.66) (37.76) (42.97) (28.13) (53.05)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE (15.14) (3.46) (41.16) (70.17) (173.84) (464.06) (256.66) (220.02) (58.08) (90.27)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Silence Therapeutics PLC Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ZVRA Zevra Therapeutics, Inc. $609.9M 10.5× 10.5× +53.25% (above 0%: growing) −88.71% (below 0%: shrinking) +670.87% (above 0%: growing) 96.16% 42.30% Compare
PHAT Phathom Pharmaceuticals, Inc. $606.8M — (loss-making) — (loss-making) +88.02% (above 0%: growing) n/m +96.86% (above 0%: growing) 79.68% (5.34%) Compare
OLMA Olema Pharmaceuticals, Inc. $601.1M — (loss-making) — — n/m −54.33% (below 0%: shrinking) 0.00% 0.00% Compare
CRMD CorMedix Inc $581.5M 3.0× 16.5× +156.52% (above 0%: growing) +13.79% (above 0%: growing) +185.90% (above 0%: growing) 75.66% 42.10% Compare
SLN Silence Therapeutics PLC Sponsored ADR $581.1M — (loss-making) — (loss-making) +197.18% (above 0%: growing) n/m +106.95% (above 0%: growing) 97.39% 0.00%
SGMT Sagimet Biosciences Inc. $574.7M — (loss-making) — (loss-making) — n/m −21.95% (below 0%: shrinking) 100.00% 0.00% Compare
DBVT DBV Technologies S.A. $572.6M — (loss-making) — −53.33% (below 0%: shrinking) n/m −56.15% (below 0%: shrinking) 100.00% (7,228.57%) Compare
VALN Valneva SE Sponsored ADR $560.4M 59.7× 19.4× −17.29% (below 0%: shrinking) n/m −56.05% (below 0%: shrinking) 15.29% (76.67%) Compare
STTK Shattuck Labs, Inc. $555.0M — (loss-making) — (loss-making) −10.31% (below 0%: shrinking) n/m +1.01% (above 0%: growing) 100.00% 0.00% Compare
Median of peers $578.1M 10.5× 16.5× +21.47% — −10.47% 87.92% 0.00%

All 614 Biotechnology stocks →

Silence Therapeutics PLC Sponsored ADR (SLN) key facts

  • Concern: Silence Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $559,000.00, down 98.7% from fiscal 2024.
  • Silence Therapeutics PLC Sponsored ADR (SLN) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, SLN traded at $8.68, a market capitalization of $581.1 million.
  • Return on equity was −90.3% and debt-to-equity 0.00.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −4.82 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Silence Therapeutics PLC Sponsored ADR (SLN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/SLN · Data as of Mar 31, 2026 · For information only; not investment advice. · © 2026 stockrow.com